Quantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: Its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension

Proteomics

Volumn 11, Issue 13, 2011, Pages 2727-2737

  Araki, Yoshihiko ^a   Nonaka, Daisuke ^b   Tajima, Atsushi ^c   Maruyama, Mayuko ^a   Nitto, Takeaki ^d   Ishikawa, Hitoshi ^e   Yoshitake, Hiroshi ^a   Yoshida, Emiko ^b   Kuronaka, Noriko ^b   Asada, Kyoichi ^b   Yanagida, Mitsuaki ^a   Nojima, Michio ^c   Yoshida, Koyo ^c   Takamori, Kenji ^a   Hashiguchi, Teruto ^f   Maruyama, Ikuro ^f   Lee, Lyang Ja ^b   Tanaka, Kenji ^b  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Protosera Inc   (Japan)

^c JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^d YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^e Yamagata Saisei Hospital   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Anti human serum albumin column; Biomedicine; Biomonitoring method; Peptidomics; Preeclampsia; Serum biomarkers

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; FETUIN A; FIBRINOGEN; FIBRINOGEN ALPHA; IMMUNOGLOBULIN G; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; KININOGEN; KININOGEN I; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MATERNAL HYPERTENSION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ONE STEP DIRECT TRANSFER TECHNOLOGY; PATHOPHYSIOLOGY; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TECHNOLOGY;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; BRADYKININ; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PEPTIDES; PREGNANCY; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 79959685539     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000753     Document Type: Article

References (44)

1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 2000, 183, S1-S22.
2. Nakayama, T., Yamamoto, T., Comparison between essential hypertension and pregnancy-induced hypertension: a genetic perspective. Endoc. J. 2009, 56, 921-934.
3. Sibai, B. M., Dekker, G., Kupferminc, M., Pre-eclampsia. Lancet 2005, 365, 785-799.
4. Furuya, M., Ishida, J., Inaba, S., Kasuya, Y. et al., Impaired placental neovascularization in mice with pregnancy-associated hypertension. Lab. Invest. 2008, 88, 416-429.
5. Furuya, M., Ishida, J., Aoki, I., Fukamizu, A., Pathophysiology of placentation abnormalities in pregnancy-induced hypertension. Vasc. Health Risk Manag. 2008, 4, 1301-1313.
6. Hornig, C., Barleon, B., Ahmad, S., Vuorela, P. et al., Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab. Invest. 2000, 80, 443-454.
7. Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H. et al., Excess placental soluble fms-like tyrosine kinase1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111, 649-658.
8. Mahmoudi, N., Graves, S. W., Solomon, C. G., Repke, J. T. et al., Eclampsia: 13-year experience at a United States tertiary care center. J. Womens Health Gender Based Med. 1999, 8, 495-500.
9. de Swiet, M., Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom. Am. J. Obstet. Gynecol. 2000, 182, 760-766.
10. Carty, D. M., Delles, C., Dominiczak, A. F., Novel biomarker for predicting preeclampsia. Trends Cardiovasc. Med. 2008, 18, 186-194.
11. Hawfield, A., Freedman, B. I., Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther. Adv. Cardiovasc. Dis. 2009, 3, 65-73.
12. Grill, S., Rusterholz, C., Zanetti-Dällenbach, R., Tercanli, S. et al., Potential marker of preeclampsia - a review. Reprod. Biol. Endocrinol. 2009, 7, 70.
13. Blumenstein, M., McMaster, M. T., Black, M. A., Wu, S. et al., A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009, 9, 2929-2945.
14. Thachil, J., Toh, C. H., Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev. 2009, 23, 167-176.
15. Richter, R., Schulz-Knappe, P., Schrader, M., Ständker, L. et al., Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B Biomed. Sci. Appl. 1999, 726, 25-35.
16. Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J. et al., Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics 2003, 2, 1096-1103.
17. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
18. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
19. Petricoin E. F., 3rd, Ornstein, D. K., Paweletz, C. P., Ardekani, A. et al., Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 2002, 94, 1576-1578.
20. Petricoin, E. F., Fishman, D. A., Conrads, T. P., Veenstra, T. D., Liotta, L. A., Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 2004, 4, 2357-2360.
21. Petricoin, E. F., Belluco, C., Araujo, R. P., Liotta, L. A., The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 2006, 6, 961-967.
22. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
23. Teng, P-N., Bateman, N. W., Hood, B. L., Conrads, T. P., Advances in proximal fluid proteomics for disease biomarker discovery. J. Proteome Res. 2010, 9, 6091-6100.
24. Oleschuk, R. D., Mccomb, M. E., Chow, A., Ens, W. et al., Characterization of plasma proteins adsorbed onto biomaterials. By MALDI-TOFMS. Biomaterials 2000, 21, 1701-1710.
25. Tracy, M. B., Chen, H., Weaver, D. M., Malyarenko, D. I. et al., Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment. Proteomics 2008, 8, 1530-1538.
26. Tanaka, K., Tsugawa, N., Kim, Y. O., Sanuki, N. et al., A new rapid and comprehensive peptidome analysis by one-step direct transfer technology for 1-D elecrophoresis/MALDI mass spectrometry. Biochem. Biophys. Res. Commun. 2009, 379, 110-114.
27. Lowenthal, M. S., Mehta, A. I., Frogale, K., Bandle, R. W. et al., Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 2005, 51, 1933-1945.
28. Granger, J., Siddiqui, J., Copeland, S., Remick, D., Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5, 4713-4718.
29. Stephens, M. A., EDF statistics for goodness of fit and some comparisons. J. Am. Stat. Assoc. 1974, 69, 730-737.
30. Altman, D. G., in: Altman, D. G., (Ed.), Practical Statistics for Medical Research, Non-Parametric Methods, Chapman and Hall, London 1971, pp. 171-173.
31. Delong, E. R., Delong, D. M., Clarke-Pearson, D. L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44, 837-845.
32. Youden, W. J., Index for rating diagnostic tests. Cancer 1950, 3, 32-35.
33. Barsnes, H., Huber, S., Sickmann, A., Eidhammer, I., Martens, L., OMSSA Parser: an open-source library to parse and extract data from OMSSA MS/MS search results. Proteomics 2009, 9, 3772-3774.
34. Bryant, J. W., Shariat-Madar, Z., Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc. Hematol. Agents Med. Chem. 2009, 7, 234-250.
35. Ikari, N., Sugo, T., Fujii, S., Kato, H., Iwanaga, S., The role of bovine high-molecular-weight (HMW) kininogen in contact-mediated activation of bovine factor XII: interaction of HMW kininogen with kaolin and plasma prekallikrein. J. Biochem. 1981, 89, 1699-1709.
36. Tait, J. F., Fujikawa, K., Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen: a region from residues 185 to 224 of the kininogen light chain retains full binding activity. J. Biol. Chem. 1986, 261, 15396-15401.
37. DeLa Cadena, R. A., Colman, R. W., The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sci. 1992, 1, 151-160.
38. Chisolm, J. C., Handorf, C. R., Zinc, cadmium, metallothionein, and progesterone: do they participate in the etiology of pregnancy induced hypertension? Med. Hypotheses 1985, 17, 231-242.
39. Chisolm, J. C., Handorf, C. R., Further observations on the etiology of pre-eclampsia: mobilization of toxic cadmium-metallothionein into the serum during pregnancy. Med. Hypotheses 1996, 47, 123-128.
40. Bedwal, R. S., Bahuguna, A., Zinc, copper and selenium in reproduction. Experientia 1994, 50, 626-640.
41. Hashiguchi, T., Tanaka, K., Lee, L-J., Sasaki, K. et al., Diagnostic value of peptidome analyses for protease activated pathological conditions beyond cancer diagnosis. Med. Hypotheses 2009, 73, 760-763.
42. Hayashi, C., Ono, Y., Doi, N., Kitamura, F. et al., Multiple molecular interactions implicate the connectin/titin N2A region as a modulating scaffold for p94/calpain 3 activity in skeletal muscle. J. Biol. Chem. 2008, 283, 14801-14814.
43. Hoeppe, S., Schreiber, T. D., Planatscher, H., Zell, A. et al., Targeting Peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification. Mol. Cell. Proteomics 2011, 10, M110.002857.
44. Whiteaker, J. R., Zhao, L., Abbatiello, S. E., Burgess, M. et al., Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 2011, 10, M110.005645.